Skip to main content
. 2022 May 2;23(9):5041. doi: 10.3390/ijms23095041

Figure 2.

Figure 2

Effects of olaparib and PDD00017273 on ALP activity and mRNA expression of Alp during osteoblast differentiation. (A) ALP activity in olaparib- and PDD00017273-treated MC3T3-E1 cells. MC3T3-E1 cells were treated with DMSO, 1 µM olaparib, or 1 µM PDD00017273 after incubation in differentiation medium for 0–28 days. ALP activity was measured at specified time points. (B) Levels of Alp mRNA expression determined by qRT-PCR and normalized to the mRNA expression in DMSO-treated cells on day 7 after incubation in differentiation medium. Alp expression was increased in PDD00017273-treated cells compared with olaparib-treated cells at 28 days after incubation with differentiation medium. To obtain these data, at least three independent experiments were performed. D, DMSO; OLA, 1 µM olaparib; PDD, 1 µM PDD00017273. Data are shown as mean ± SE. * p < 0.05, ** p < 0.01 (Tukey’s test).